A Pilot Study of Plinabulin and Pegfilgrastim in People with Multiple Myeloma Undergoing an Autologous Stem Cell Transplantation

Share

Full Title

Pilot Trial of Plinabulin and Pegfilgrastim to Reduce the Duration of Absolute Neutropenia After Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Purpose

High-dose chemotherapy (such as melphalan) given before autologous stem cell transplantation (ASCT) may benefit people with multiple myeloma by killing cancer cells. However, the chemotherapy causes a drop in blood cell counts, including white blood cell counts, and it can be several weeks before the counts return to normal. A decrease in blood cells can cause health problems such as tiredness, weakness, lack of appetite, and increased risk of infection.

Doctors routinely use pegfilgrastim to boost white blood cell counts in patients receiving chemotherapy. In this study, researchers are assessing the safety and effectiveness of giving the drug plinabulin with pegfilgrastim to further reduce the time it takes for blood cell counts to return to normal in people with multiple myeloma undergoing ASCT.

Plinabulin is designed to kill cancer cells by damaging blood vessels and stopping blood flow to tumors. In addition, the drug increases white blood cell counts. It is given intravenously (by vein) and pegfilgrastim is given as an injection.

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have multiple myeloma and be scheduled to receive ASCT.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people ages 18-75.

For more information about this study, please contact the office of Dr. Gunjan Shah at 212-639-8356.

Protocol

21-337

Phase

II

Investigator

Co-Investigators

Sergio Giralt